Table 5. WT instabilities using different chemical growth media.

	Genotype	Unstable Chr. (×10−5)		Allelic rec. (×10−5)		Chr. loss (×10−4)
		Median (Q1, Q3)	Fold stabil.	Median (Q1, Q3)	Fold stabil.	Median (Q1, Q3)	Fold stabil.
	ChrVII RAD+ (wild type)	6.0 (3.5, 7.6)	1	6.8 (3.5, 10)	1	3.7 (1.1, 5.2)	1
Cycloheximide	WT 0.04 μg/ml cyc.	19 (14, 27)	0.32*	6.3 (3.9, 7.1)	1.1	4.2 (1.6, 5.2)	0.88
	WT 0.06 μg/ml cyc.	22 (15, 29)	0.27*	10 (5.8, 17)	0.68	4.7 (4.2, 6.7)	0.79
D-glucosamine	WT 2% Dex, 0.2% D-gluc	7.6 (7.4, 7.9)	0.8	4.3 (2.5, 5.7)	1.6	0.52 (0, 1.1)	7.1*
	WT 2% Dex, 0.7% D-gluc	7.6 (5.2, 10)	0.79	2.9 (1.4, 4.2)	2.3	1.6 (1.1, 2.2)	2.3
	WT 2% Dex, 1.0% D-gluca	4.2 (3.9, 8.0)	1.4	4.8 (2.8, 5.6)	1.4	6.4 (0.0, 7.0)	0.58
	WT 2% Dex, 1.4% D-gluc	8.6 (7.7, 11)	0.70*	4.8 (1.6, 7.5)	1.4	5.1 (3.9, 6.9)	0.73
	WT 2% Dex, 1.8% D-gluc	8.0 (4.2, 9.5)	0.75	5.6 (4.7, 12)	1.2	2.1 (1.3, 3.6)	1.8
	WT 2% Dex, 2.0% D-gluc	9.1 (7.4, 12)	0.66	3.5 (2.4, 4.5)	1.9	3.6 (0.30, 7.3)	1.0
Myriocin	WT 200 ng/ml myriocin	6.2 (3.8, 8.9)	0.97	6.8 (5.6, 9.9)	1.0	2.1 (1.3, 2.9)	1.8
	WT 400 ng/ml myriocin	6.1 (2.5, 9.3)	0.98	4.6 (3.4, 6.5)	1.5	1.1 (1.1, 1.1)	3.4
	WT 600 ng/ml myriocin	5.6 (4.7, 8.0)	1.1	6.5 (3.8, 11)	1.0	0.0 (0.0, 1.0)*	N/A
YEPG	WT 2% glycerol	3.2 (1.7, 8.9)	1.9	4.9 (3.1, 40)	1.4	61 (2.1, 420)	0.06

Instability frequencies and genome fold stabilization of WT cells grown on media plates containing D-glucosamine, myriocin, YEPG (glycerol), and cycloheximide normalized to WT cells grown on YEPD. Cells with a light gray background indicate genome fold stabilization increase; cells with a white background indicate decreased fold stabilization (<1.0 = increased instability) or no change in stabilization (=1.0). Statistically significant appears in boldface type. Kruskal–Wallis test, * P < 0.01. N/A, not applicable.

^aSample size N = 5.